id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-2655-0008,FDA,FDA-2015-E-2655,Certificate of Extension from FDA CDER to Novartis Pharmaceuticals Corp.,Other,Certificate Extending Patent Term,2020-07-29T04:00:00Z,2020,7,2020-07-29T04:00:00Z,,2020-07-29T20:53:23Z,,0,0,09000064847b7bef
FDA-2015-E-2655-0007,FDA,FDA-2015-E-2655,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T16:49:33Z,,0,0,090000648357d7df
FDA-2015-E-2655-0006,FDA,FDA-2015-E-2655,Determination of Regulatory Review Period for Purposes of Patent Extension; ZYKADIA,Notice,Determinations,2017-12-26T05:00:00Z,2017,12,2017-12-26T05:00:00Z,2018-02-27T04:59:59Z,2017-12-26T16:01:36Z,2017-27745,0,0,0900006482d72685
FDA-2015-E-2655-0005,FDA,FDA-2015-E-2655,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-05T04:00:00Z,2017,6,2017-06-05T04:00:00Z,,2017-06-05T19:43:51Z,,0,0,09000064826929b4
FDA-2015-E-2655-0004,FDA,FDA-2015-E-2655,Letter from U.S. Patent and Trademark Office to cder,Other,Letter(s),2016-11-23T05:00:00Z,2016,11,2016-11-23T05:00:00Z,,2016-11-23T12:52:08Z,,0,0,09000064823b9438
FDA-2015-E-2655-0003,FDA,FDA-2015-E-2655,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-10-20T04:00:00Z,2015,10,2015-10-20T04:00:00Z,,2015-10-20T16:29:33Z,,0,0,0900006481ccfe45
FDA-2015-E-2655-0001,FDA,FDA-2015-E-2655,Patent Extension Application from NOVARTIC PHARMACEUTICAL CORP (on behalf of NOVARTIC AG),Other,Application,2015-07-27T04:00:00Z,2015,7,2015-07-27T04:00:00Z,,2015-07-27T11:55:45Z,,0,0,0900006481ba56a6
FDA-2015-E-2655-0002,FDA,FDA-2015-E-2655,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-07-27T04:00:00Z,2015,7,2015-07-27T04:00:00Z,,2015-07-27T11:55:51Z,,0,0,0900006481ba56a4